Galapagos (GLPG) Stock Price, News & Analysis

Company Overview

Galapagos NV (NASDAQ:GLPG) is a biotechnology company focused on the discovery, development and commercialization of small molecule medicines with novel modes of action. Founded in 1999 and headquartered in Mechelen, Belgium, Galapagos has built a deep pipeline of therapeutic candidates in areas such as inflammation, fibrotic diseases and oncology. The company’s discovery engine combines proprietary target identification and validation platforms with extensive medicinal chemistry expertise to advance programs from early research through clinical development.

One of Galapagos’s lead assets is filgotinib, an oral JAK1 selective inhibitor for the treatment of rheumatoid arthritis and other inflammatory diseases, in partnership with Gilead Sciences. The collaboration with Gilead, initiated in 2019, extends across multiple indications and has accelerated the global development and commercialization efforts for filgotinib. Other pipeline candidates include inhibitors targeting connective tissue disease-associated interstitial lung disease and novel anti-fibrotic agents designed to address high unmet medical needs.

Galapagos maintains research and development operations in Europe and the United States, with additional facilities in Leiden, the Netherlands, and Boston, Massachusetts. This geographic footprint allows the company to leverage diverse scientific talent and regulatory expertise, positioning its programs for efficient clinical progression across multiple regions. Galapagos is also engaged in strategic partnerships and licensing arrangements to complement its internal R&D capabilities and expand access to potential therapies worldwide.

Leadership at Galapagos is headed by Chief Executive Officer Paul Stoffels, M.D., who brings decades of pharmaceutical and biotech experience, including former roles at Johnson & Johnson. Working alongside a management team of seasoned drug developers and regulatory experts, the company continues to execute on its mission to transform the lives of patients with serious diseases. Supported by a robust governance framework and a commitment to scientific innovation, Galapagos aims to advance its portfolio toward regulatory approval and commercial success in the coming years.

Key Stats

• Today's Range: $30.05 to $30.64
• 50-Day Range: $25.07 to $29.85
• 52-Week Range: $22.36 to $31.23
• Volume: 337,102 shs
• Average Volume: 252,275 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.33
• Consensus Rating: Reduce

Galapagos Stock Analysis - MarketRank™

Galapagos scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Galapagos has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 4 hold ratings, and 4 sell ratings.

Amount of Analyst Coverage

Galapagos has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Galapagos are expected to decrease in the coming year, from ($1.60) to ($3.11) per share.

Price to Book Value per Share Ratio

Galapagos has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.99% of the float of Galapagos has been sold short.

Short Interest Ratio / Days to Cover

Galapagos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galapagos has recently increased by 1.38%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galapagos does not currently pay a dividend.

Dividend Growth

Galapagos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.99% of the float of Galapagos has been sold short.

Short Interest Ratio / Days to Cover

Galapagos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galapagos has recently increased by 1.38%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: 0.22

News Sentiment

Galapagos has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Galapagos this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galapagos insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.91% of the stock of Galapagos is held by insiders.

Percentage Held by Institutions

Only 32.46% of the stock of Galapagos is held by institutions.

GLPG Stock Analysis - Frequently Asked Questions

How have GLPG shares performed this year?

Galapagos' stock was trading at $27.50 at the beginning of the year. Since then, GLPG stock has increased by 10.9% and is now trading at $30.49.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) announced its quarterly earnings results on Wednesday, April, 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $2.24. The biotechnology company earned $97.33 million during the quarter, compared to analyst estimates of $72.22 million.
Read the conference call transcript.

When did Galapagos IPO?

Galapagos (GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who are Galapagos' major shareholders?

Galapagos' top institutional shareholders include Moody National Bank Trust Division.

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLPG
• CIK: 1421876
• Web: www.glpg.com
• Phone: (321) 534-2900
• Fax: 321-534-2901
• Employees: 1,310
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Galapagos: $25.33
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: -16.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.95
• Quick Ratio: 7.86

Sales & Book Value

• Annual Sales: $298.31 million
• Price / Sales: N/A
• Cash Flow: $0.77 per share
• Price / Cash Flow: 39.68
• Book Value: $47.57 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: 0.07